Monograph Details
|
|
Endocrine System
> Diabetes
|
|
JANUVIA |
| Manufacturer |
|
Merck & Co., Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Dipeptidyl peptidase-4 inhibitor. |
| Generic Name |
|
Sitagliptin (as phosphate) 25mg, 50mg, 100mg; tabs. |
| Indications |
|
Adjunct to diet and exercise in type 2 diabetes, as monotherapy or combination therapy (see literature). |
| Children |
|
<18yrs: not recommended. |
| Adults |
|
100mg once daily. Renal insufficiency: CrCl ≥30–50mL/min: 50mg once daily; CrCl<30mL/min or on dialysis: 25mg once daily. |
| Contraindications |
|
Not for the treatment of type 1 diabetes or diabetic ketoacidosis. |
| Precautions |
|
Monitor renal function before starting therapy, then periodically. Severe hepatic insufficiency. Pregnancy (Cat.B). Nursing mothers. |
| Interactions |
|
Concomitant sulfonylurea: may need lower dose of sulfonylurea to reduce risk of hypoglycemia. Monitor digoxin. |
| Adverse Reactions |
|
Nasopharnygitis, upper respiratory tract infection, headache; hypersensitivity reactions (eg, anaphylaxis, angioedema, Stevens-Johnson syndrome), discontinue if occur. |
| How Supplied |
|
Tabs—30, 90, 100 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
